Mini Review


N Popovski1 and A Nikolov2*

1Department of Obstetrics and Gynecology, Medical University, Pleven, Bulgaria
2Institute for Scientific Research, Medical University, Pleven, Bulgaria

*Corresponding author: A Nikolov, Institute for Scientific Research, Medical University, Pleven, Bulgaria

ARTICLE INFO

Received: November 15, 2019
Published: November 22, 2019


Introduction

In the current review we would like to give our comments on the most important aspects of NEWSLETTER No.212/2019 clinical behaviour “Pregnancy and Cardiovascular Disease”. The Working Group for the Study of pregnancy and hypertension was established in 2011 as part of the presidential initiative of ACOG, which focuses on pre-eclampsia and hypertension during pregnancy. The Working Group is chaired by Dr. James M. Roberts of the University of Pittsburgh and includes 17 internationally recognized experts in hypertension during pregnancy. Bulletin No.212/2019 clarifies the classification system for hypertensive disorders in pregnancy, identifying problems in the treatment of pre-eclampsia, eclampsia and chronic hypertension in pregnancy that deserve special attention and emphasizes the potential impacts of the conditions later in life of the patient.

Preeclampsia, eclampsia and HELLP syndrome affect many women and lead to a high percentage of maternal and perinatal complications [1]. It is important for clinicians to accurately diagnose the conditions to prevent any adverse outcome. In most cases, classic presentation with hypertension and proteinuria in pregnancy >20 g.w. is observed. However, recent studies show that some women develop preeclampsia without showing any classic symptoms. Atypical cases are those that may develop before 20 g.w. or with signs and symptoms of preeclampsia without hypertension or proteinuria, or those with mild abnormalities in laboratory tests [2].

In the countries of South America and those in the Caribbean hypertensive disorders account for almost 26% of deaths among mothers, while in Africa and Asia contribute about 9% of deaths [3].
Although maternal mortality is significantly lower in high-income countries than in developing countries, 16% of maternal mortality may be due to hypertensive disorders. In the United States, the rate of preeclampsia has increased by 25% between 1987 and 2004 [4]. Moreover, compared to women who gave birth in 1980, those who gave birth in 2003 were 6.7 times more likely to have complications from severe preeclampsia. Treatment of preeclampsia requires many resources: for example, in 2016 in the United States treatment cost of preeclampsia during the first 12 months after delivery are worth 2.18 billion dollars (1.03 billion dollars for women and 1.15 billion dollars for new borns together).

**Data from Practice Bulletin of the American College of Obstetrics and Gynaecologists 2019**

**Recommendations for Therapeutic Strategy in Gestational Hypertension/ Preeclampsia**

a) In women with gestational hypertension or preeclampsia at 37 weeks gestation or later without severe pathology delivery is recommended.

b) In patients with severe gestational hypertension or preeclampsia/eclampsia Magnesium sulfate should be started for prevention of seizures.

c) Patients should receive low dose aspirin (81mg/day) for prevention of preeclampsia between 12 and 28 g.w., if a high-risk factors for pre-eclampsia exist, such as:

I. Multiple pregnancy
II. Previous pregnancy with preeclampsia
III. kidney disease
IV. Autoimmune disease
V. Type 1 or type 2 diabetes mellitus
VI. Chronic hypertension
VII. Or more than one moderate risk factor, such as family history of preeclampsia, maternal age over 35, first pregnancy, BMI>30, specific socio-demographic characteristics.

d) NSAIDs are thought to be advantageous over opioid analgesics.

**Recommendations for Therapeutic Strategy in Chronic Hypertension**

a) Pregnant women with chronic hypertension should also receive low-dose aspirin between 12 and 28 g.w.

b) Antihypertensive treatment should be started in women with chronic persistent hypertension with Systolic blood pressure ≥150 mmHg and/or diastolic blood pressure≥95 mmHg or at gestational hypertension, chronic hypertension with superposed gestational hypertension or hypertension with subclinical organ damage with systolic blood pressure ≥ 140mmHg and /or diastolic pressure ≥ 90 mmHg.

c) It is possible to start antihypertensive treatment even in patients with lower values of blood pressure according to the ongoing diseases or if there is an evidence of renal dysfunction.

d) ACOG recommends that pregnant women with arterial hypertension to be treated according to recently revised criteria of the American College of Cardiology (ACC) and American Heart Association (AHA), which classifies arterial hypertension in the following categories:

I. Normal Systolic BP ≤120 mmHg; Diastolic BP ≤ 80 mmHg.

II. Increased Systolic BP 120-129 mm Hg; Diastolic BP ≥ 80 mmHg.

III. Stage 1 hypertension – Systolic BP 130-139 mmHg; Diastolic BP 80-89 mmHg.

IV. Stage 2 hypertension – Systolic BP ≥ 140 mmHg; Diastolic BP ≥ 90 mmHg.

Those guidelines show that the range for normal blood pressure of not pregnant women has a lower threshold for diagnosis of hypertension in comparison with the criteria of ACOG. This is likely to lead to an overall increase in patients classified with chronic hypertension and will require co-decision by the obstetrician and cardiologist, as well as by the patient regarding appropriate guideline during pregnancy [5].

**Summary of the most important recommendations of the Working Group on Hypertension in Pregnancy:**

a) Careful and complete patient’s history taking to assess risk factors.

b) Vitamin C or Vitamin E are not recommended to prevent preeclampsia.

c) A daily low dose of aspirin for prevention of preeclampsia is recommended for very high risk patients.

d) Initiation of an antihypertensive medicament is recommended for severe hypertension during pregnancy.

e) The decision for delivery should not be based on severity of proteinuria

f) The use of magnesium sulfate is recommended for severe preeclampsia, edema or HELLP syndrome.

According to the report of the working group on ACOG of hypertension in pregnancy the diagnosis preeclampsia still requires quantitative measurement of protein in urine. The work group recommends that clinicians should also consider other factors, in addition to high blood pressure to diagnose preeclampsia without delay [6].
The incidence of preeclampsia in the USA has markedly increased with 25% over the past two decades and it is the leading cause of maternal and neonatal morbidity and mortality. Pre-eclampsia is a serious condition that usually begins after 20 g.w., and high arterial pressure is a major factor. Women who have chronic hypertension and have had preeclampsia during a previous pregnancy of 35 years or more, who have more than one fetus, have diabetes or renal disease, are with obesity. Afro-American have an autoimmune disorders are at increased risk of developing of pre-eclampsia. Signs of preeclampsia include severe headache, vision disorders, rapid weight gain, abdominal pain and swelling. Definitive treatment of preeclampsia is delivery [7].

Preeclampsia affects many women (about 5% of pregnant women) and there are so many potentially dangerous complications, including preterm birth, severe hypertension, stroke and seizures—even mortality. Early detection and adequate treatment are a socially significant problem. According to the Working Group on the Study of Preeclampsia, it leads to a number of future cardiovascular and metabolic diseases. Women with a history of pre-eclampsia have 1.5 to 2 times higher risk of developing heart disease later in life. Although, preeclampsia causes no direct cardiac disease, both states have common risk factors.

Women who have had hypertension or pre-eclampsia in a previous pregnancy have a higher than normal recurrence rate for both conditions in a subsequent pregnancy. Depending on which stage in the pregnancy occurred and whether the woman is overweight or have diabetes, a renal disease or other forms of vascular disease, the risk of recurrence can reach up to 50%. Unfortunately, the Working Group for the Study of preeclampsia is having not still detected any effective screening test for prognosis of preeclampsia development.

**Highlights of 2019 Task of Working Group for Hypertension During Pregnancy:**

- a) Careful and complete history taking to assess risk factors.
- b) Vitamin C or Vitamin E are not recommended to prevent preeclampsia.
- c) Daily low-dose aspirin for prevention of pre-eclampsia is recommended for women who are with higher risk with a history of pre-eclampsia and premature birth.
- d) Antihypertensive medication is recommended for systolic blood pressure ≥ 150mmHg and/or diastolic blood pressure ≥ 95mmHg in persistent hypertension or in gestational hypertension, chronic hypertension with superposed gestational hypertension or hypertension with subclinical organ damage with systolic arterial pressure ≥ 140mmHg and/or diastolic pressure ≥ 90 mm Hg.
- e) Decision of delivery should not be based on the degree of proteinuria.
- f) Use of magnesium sulfate is recommended for severe preeclampsia, eclampsia or HELLP syndrome [8].

**Take Home Messages**

- a) Hypertensive disorders during pregnancy are a leading cause of maternal and perinatal mortality worldwide.
- b) Pre-eclampsia complicates 2% to 8% of pregnancies worldwide. In the USA, preeclampsia rates increased by 25% between 1987 and 2004. Preeclampsia treatment requires great resources.
- c) Accepted are current clinical guidelines Bulletin № 212/2019 of ACOG for algorithm for diagnosing, treatment of gestational hypertension and preeclampsia, time of delivery and the use of magnesium sulfate.
- d) Pregnant women with moderate to high risk for developing preeclampsia should receive 81 mg of aspirin, and ideally it should be started between 12 and 16 weeks of gestation.
- e) Treatment of gestational hypertension is at the same time and the treatment of preeclampsia, these two states can be regarded as a general spectrum of the same disease.
- f) ACOG also stresses that it is a priority to immediately treat the emergent hypertensive conditions, rather than to wait four hours to put the diagnose according to previous recommendations.
- g) Non-steroid anti-inflammatory agents are now recommended as a first line treatment of pain postpartum over opioids, because they don’t affect the values of the arterial pressure.
- h) ACOG continues to recommend quantitatively determination of protein in urine for 24 hour or protein/creatinine ratio; but if these tests are not available, proteinuria should be diagnosed as 2+ per test strip instead of 1+.

**Conclusion**

Hypertensive disorders in pregnancy are one of the most frequent reasons for maternal and perinatal mortality worldwide. Pre-eclampsia complicates 2-8% of pregnancies worldwide. Although current changes of guidelines for clinical judge on pregnancy and hypertension are not yet cardinal, they need to help treatment updates of preeclampsia and related pregnancy hypertensive conditions. The latest newsletter with guidelines for behaviour of ACOG in 2019 on "Pregnancy and Cardiovascular Disease" provides a clear recommendations focusing on the right time treatment of chronic hypertension, gestational hypertension, preeclampsia/eclampsia, preeclampsia/eclampsia, pregnancy and acute hypertensive conditions, as well as treatment of pain postpartum in women with arterial hypertension.

**References**


ISSN: 2574-1241

DOI: 10.26717/BJSTR.2019.23.003861

A Nikolov. Biomed J Sci & Tech Res

This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php

https://biomedres.us/

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles